Novartis Likely to Beat Expectations as Generic Headwinds Fade
Dow Jones11-06
1228 GMT - Novartis is likely to beat and raise expectations next year and beyond, as generic headwinds that held its results back over the past year start to fade, Citi analysts say in a note. With those headwinds subsiding, the Swiss drugmaker is expected to report sales growth of 9% at constant currency for 2027, with a core operating margin of 39.9%, close to its 2029 target of 40%, according to Citi. Over the 2025-30 period, the company is expected to post annual sales growth of 5.3%, the analysts say. Citi raises its target price on Novartis's stock to 150 Swiss francs from 135 francs. Shares fall 2.5% to 130.84 francs.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments